Integrated layer
PEPDIA-INT-039569
Sequence 2 from Patent US 20030195150
TTMPLW
Primary-literature peptide layer
PEPDIA-PLP-001508
BP203
KKLFKKILRYLNH
125 observations · 2 papers
Primary literaturePEPDIA-PLP-001674
MAP-0403_J-2
KWLRRPWRRWRNH
95 observations · 1 papers
Primary literaturePEPDIA-PLP-001978
M104
MEAFIVSAFKHQAEGFKLHYK
85 observations · 1 papers
Primary literaturePEPDIA-PLP-001507
BP100
KKLFKKILKYLNH
82 observations · 3 papers
Primary literaturePEPDIA-PLP-001966
MR-22
MAKRRKKAKKKAKKAKKRRRRRNH
71 observations · 1 papers
Primary literaturePEPDIA-PLP-001822
LRGG_chem
LLRLLRRGGRRLLRLLNH
68 observations · 1 papers
Evidence inquiry layer
Both of them had a pronounced reduction of their viabilities when treated with bioengineered OMVs ... while OMV^MPI-C had the lowest half-maximal inhibitory concentration (IC50) (Figures 2B, C).
Both of them had a pronounced reduction of their viabilities when treated with bioengineered OMVs ... while OMV^MPI-C had the lowest half-maximal inhibitory concentration (IC50) (Figures 2B, C).
The results presented in Figure 2F manifested the percentage of apoptotic MB49 cells increased to 44.3% in OMV^MPI-C group, much higher than the 8.43% in PBS group and 11.0% in OMV^WT group.
